NAS10031,225+0.48%S&P7,819+0.58%GOLD$4,185+0.68%BTC$85,431−0.41%VIX15.01−3.29%live tape · as of 01:04 UTC
The Screen · Healthcare · Biotechnology
Vir Biotechnology, Inc.
VIR · Nasdaq · USD · Market cap $2.0B · 367 employees
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
FAIL · Does not pass the screen
11.60 USD
Screen close, 2026-10-06 · not a live quote
Screened 2026-10-06 · the tape above runs as of 01:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 11.60 against the desk's fair-value range, base estimate 20.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price11.60 USD
Fair value20.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown10.60+9.4% to today
2026-09-16Read Accumulation11.31+2.6% to today ✓
2026-07-02Read Markdown8.61+34.7% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Vir Biotechnology, Inc. holds its Markdown at $11.60. The statistical read favours the sellers, held for 45 days.
As held on the ledger · 2026-10-06
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 45 days
Price at the screen
$11.60
Valuation
N/A trailing · -4.66 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.59
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
9.76%
Below 33%
Interest-bearing debt is just 9.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
31.37%
Below 33%
Cash held in interest-bearing accounts and securities is 31.4% of assets, under the one-third limit.
Pass
Receivables
23.15%
Below 49%
Money owed to the company is 23.2% of assets, under the 49% limit.
Pass
Revenue purity
60.49%
Below 5%
60.5% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Vir Biotechnology, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 60% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 2026-10-07. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-06 screen. The gold marker is the market price at the same screen. A 72.4% margin of safety to the base estimate.
Third-party analyst targets: 9 covering, consensus Strong Buy. The average target sits +72% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical stage bets rarely deliver on paper promise
A company whose entire value sits in unproven drugs for infectious diseases is like funding a race car that has never left the workshop. Vir Biotechnology trades at half our calculated fair value with a forward multiple that reflects deep losses, yet the opportunity rating stays at none because clinical pipelines this early carry failure rates that wipe out capital fast.
The business shows zero profit margins and a negative return on equity of 48 percent, which is normal for a firm still burning cash on trials. Even with an ethical screen that passes cleanly and analyst targets clustered around 21 dollars, the absence of any moat or commercial product leaves the upside looking more like a lottery ticket than a repeatable business.
Risk sits in the binary outcomes of late stage data and dilution that often follows missed milestones. Currency or market swings matter less here than the simple fact that most such pipelines never reach paying customers. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
VIR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$10.60-6.3%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 52%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (9 analysts) rates it strong buy, with a mean price target of $21.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 26.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 52%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (9 analysts) rates it strong buy, with a mean price target of $21.
2026-08-16Markdown$8.96+4.1%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 52%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (9 analysts) rates it strong buy, with a mean price target of $21.
2026-07-18Markdown$8.61+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 52%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (9 analysts) rates it strong buy, with a mean price target of $21.
2026-07-03Markdown$8.61+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$8.61Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
